8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2016 (January 24, 2016)

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

Delaware	1-32302	41-1350192
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
100 Princeton South, Suite 300, Ewing, NJ		08628
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone, including area code: (609) 359-3020

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b)  On January 24, 2016, at the request of the Antares Pharma, Inc. (“Antares”) Board of Directors, Eamonn P. Hobbs resigned as President and Chief Executive Officer of Antares and as a member of the Antares Board of Directors.  Mr. Hobbs’ last day of employment was January 24, 2016 (“Separation Date”).  

The Company and Mr. Hobbs are parties to an Employment Agreement, dated June 23, 2014, filed with the Securities and Exchange Commission as Exhibit 10.2 to Antares’ Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014 (the “Employment Agreement”), which provides for certain severance payments and benefits subject to the execution and non-revocation by Mr. Hobbs of a written release in a form acceptable to Antares.  If Mr. Hobbs provides the release and continues to comply with the obligations contained in the Employment Agreement, Mr. Hobbs will receive severance payments and benefits in accordance with terms of the Employment Agreement.  Antares will provide such severance payments and benefits upon agreement between Antares and Mr. Hobbs on a separation and release agreement.

The foregoing is a summary description of Mr. Hobbs’ rights under the terms of the Employment Agreement and, by its nature, is incomplete.  

(c)  In connection with Mr. Hobbs’ departure, the Board of Directors of Antares appointed Robert F. Apple as President and Chief Executive Officer.  Mr. Apple will serve as the principal executive officer of Antares.  Mr. Apple will cease to serve as Chief Operating Officer in connection with his assumption of the role of President and Chief Executive Officer.

Item 7.01.Regulation FD Disclosure.

On January 26, 2016, Antares issued a press release announcing the appointment of Robert F. Apple President and Chief Executive Officer of Antares.

The full text of such press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated January 26, 2016, issued by Antares Pharma, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ANTARES PHARMA, INC.
Date:	January 27, 2016	By:	/s/ Peter J. Graham
		Name:	Peter J. Graham
		Title:	Senior Vice President, General Counsel, Chief Compliance Officer, Human Resources and Secretary

EX-99.1

EX-99.1

NEWS RELEASE

ANTARES PHARMA ANNOUNCES CEO TRANSITION

ROBERT APPLE APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER

EWING, NJ, January 26, 2016 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that its Board of Directors has appointed Robert Apple to the position of President and Chief Executive Officer.   Mr. Apple most recently served as the Company’s Executive Vice President and Chief Operating Officer.  Mr. Apple succeeds Eamonn P. Hobbs whose employment with the Company ended on January 24, 2016. Mr. Hobbs also resigned as a member of the Board of Directors.

Dr. Leonard S. Jacob, Chairman of the Antares Board of Directors stated, “Bob has been an exceptional leader during his career at Antares and we are fortunate to have an individual in our succession plan that we believe can have an immediate positive impact on the Company.  Dr. Jacob continued, “On behalf of the Antares Board, I’d like to thank Eamonn for his many contributions, both as a Board member and then subsequently as the CEO, and wish him much success in his future endeavours.”  

“I’m excited to assume the role of President and CEO at this important time in the Company’s history,” stated Bob Apple.  “I believe that we are poised to deliver on several catalysts over the next 12 months including the mid-year launch of the sumatriptan auto injector, the filing of the QuickShot testosterone new drug application with the U.S. FDA, a potential approval and launch of the epinephrine auto injector and growth in our alliance business through additional collaborations.”  

Mr. Apple joined the Company in February 2006 as the Senior Vice President and Chief Financial Officer, and was promoted to Executive Vice President, Chief Operating Officer in September 2014.  Prior to joining Antares Pharma, Mr. Apple was employed by InKine Pharmaceutical Company, Inc. from 1997 to 2005 where he served initially as the Chief Financial Officer before his promotion to the role of Chief Operating and Financial Officer. Mr. Apple was previously employed by Arthur Anderson & Company LLP. and he is a Certified Public Accountant.

ABOUT ANTARES PHARMA

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP™ (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot^® Testosterone for testosterone replacement therapy, and has recently received a therapeutically equivalent approval for VIBEX^® Sumatriptan USP for the acute treatment of migraines.  The Company's technology platforms include VIBEX^® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX^® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen.  Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.

1 of 2

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: the timing of the launch of Vibex Sumatriptan Injection USP and the amount of revenue from the same, the timing and results of the phase 3 studies for QuickShot^® Testosterone (QS T) and acceptance of the data by the U.S. Food and Drug Administration (FDA); the Company’s ability to successfully complete a New Drug Application for QS T and submit to the FDA and approval of the same by the FDA; approval by the FDA of the VIBEX^® Epinephrine Pen,  the timing and therapeutic equivalence rating thereof, and any revenue pre or post FDA approval;  FDA action with respect to the ANDA filed for the Exenatide pen; continued growth of prescriptions and sales of OTREXUP™;  the timing and results of research projects, clinical trials,  and product candidates in development; actions by the FDA or other regulatory agencies with the respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to enter into new alliance business; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2014, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contact:

Jack Howarth

Vice President, Corporate Affairs

609-359-3016

jhowarth@antarespharma.com

2 of 2